JMI Laboratories, North Liberty, Iowa, USA.
Microb Drug Resist. 2020 Aug;26(8):934-943. doi: 10.1089/mdr.2019.0104. Epub 2020 Feb 12.
This study evaluated the antimicrobial activity of telavancin against a large collection of Gram-positive pathogens of clinical importance, which were collected worldwide from 2015 through 2017, including methicillin-resistant (MRSA), coagulase-negative staphylococci, spp., β-hemolytic streptococci (BHS), , and viridans group streptococci (VGS). This report completes 7 years of continuous surveillance data for telavancin using the approved reference method for testing methodology that includes the addition of polysorbate 80. For isolates collected from 2015 through 2017, telavancin exhibited potent activity against the following species and groups that have Clinical and Laboratory Standards Institute (CLSI)-approved interpretive criteria: MRSA (MIC value, 0.06 μg/mL; 100% susceptible), vancomycin-susceptible (MIC value, 0.25 μg/mL; 99.9% susceptible), BHS (MIC value, 0.03 μg/mL; 100% susceptible), and VGS (MIC value, 0.03 μg/mL; 99.0% susceptible). Importantly, telavancin maintained excellent antimicrobial activity against multidrug-resistant subsets of these pathogen groups and against ceftaroline-nonsusceptible (telavancin MIC value, 0.06 μg/mL; 100% susceptible) and ceftaroline-resistant (telavancin MIC value, 0.12 μg/mL; 100% susceptible) isolates.
本研究评估了替拉万星对临床重要的大量革兰阳性病原体的抗菌活性，这些病原体是在 2015 年至 2017 年间从世界各地收集的，包括耐甲氧西林金黄色葡萄球菌（MRSA）、凝固酶阴性葡萄球菌、链球菌属、β-溶血性链球菌（BHS）、和草绿色链球菌（VGS）。本报告使用经过批准的检测方法参考标准完成了替拉万星 7 年的连续监测数据，其中包括添加聚山梨酯 80。对于 2015 年至 2017 年期间收集的分离株，替拉万星对以下具有临床和实验室标准协会（CLSI）批准的解释标准的物种和组表现出强大的活性：MRSA（MIC 值，0.06μg/mL；100%敏感）、万古霉素敏感（MIC 值，0.25μg/mL；99.9%敏感）、BHS（MIC 值，0.03μg/mL；100%敏感）和 VGS（MIC 值，0.03μg/mL；99.0%敏感）。重要的是，替拉万星对这些病原体组的多药耐药亚群以及对头孢他啶不敏感（替拉万星 MIC 值，0.06μg/mL；100%敏感）和头孢他啶耐药（替拉万星 MIC 值，0.12μg/mL；100%敏感）的分离株保持了出色的抗菌活性。
